Chemistry: analytical and immunological testing – Rate of reaction determination
Reexamination Certificate
2002-12-06
2008-08-26
Canella, Karen A. (Department: 1643)
Chemistry: analytical and immunological testing
Rate of reaction determination
C436S064000, C436S079000
Reexamination Certificate
active
07416893
ABSTRACT:
The present invention relates to methods of identifying drug-resistant and/or drug-sensitive cells, for example, breast cancer and brain tumor cells, on the basis of different ion and/or second messenger dynamics between a drug-sensitive and drug-resistant cell. For example, the invention provides measuring the comparative decay rates of a cellular ion, such as calcium, released into the intracellular compartment of drug sensitive and/or drug resistant cells. The present invention also provides methods for screening compounds that modulate the ionic dynamics of a cell as well as methods of determining drug resistance/sensitivity of cancer cells from cancer patients and/or designing cancer therapy based on of the ionic dynamics of cancer cells from a particular patient.
REFERENCES:
patent: 5332905 (1994-07-01), Brooker et al.
patent: 5677288 (1997-10-01), Marangos
patent: 5858713 (1999-01-01), Soderlund et al.
patent: 6171786 (2001-01-01), Shtil et al.
patent: 6420137 (2002-07-01), Strnad et al.
patent: WO 99/28747 (1999-06-01), None
Nickols and Brooker (PNAS, 1978, vol. 75, pp. 5520-5524).
Henderson et al (Journal of Biological chemistry, 1991, vol. 266, pp. 1641-1645).
abstract of Hoyal et al (Journal of Toxicology and Environmental Health, Part B, 1998, vol. 1, pp. 117-134).
abstract of Mousseau et al (European Journal of Cancer, 1993, vol. 29A, pp. 753-759).
DeBernardi and Brooker (Methods in Enzymology, 2006, vol. 414, pp. 317-335).
abstract of MacLeod (Cardioscience, 1991, vol. 2, pp. 71-85).
Adwankar et al., “Modulation of in vitro chemosensitivity by extracellular Ca++in adriamycin sensitive and resistant P388 leukemic cells,”Neoplasma37:31-36 (1990).
Altan et al., “Defective Acidification in Human Breast Tumor Cells and Implications for Chemotherapy,”J. Exp. Med. 187:1583-1598 (1998).
Barrand et al., “Multidrug Resistance-Associated Protein: A Protein Distinct from P-glycoprotein Involved in Cytotoxic Drug Expulsion,”Gen. Pharmacol. 28:639-645 (1997).
Blobe et al., “Selective Regulation of Expression of Protein Kinase C (PKC) Isoenzymes in Multidrug-resistant MCF-7 Cells,”J. Biol. Chem. 268:658-664 (1993).
Chen et al., “Identification of GlutathioneS-Transferase as a Determinant of 4-Hydroperoxycyclophosphamide Resistance in Human Breast Cancer Cells,”Biochem. Pharmacol. 49:1691-701 (1995).
Dickstein et al., “Increased Epidermal Growth Factor Receptor in an Estrogen-Responsive, Adriamycin-Resistant MCF-7 Cell Line,”J. Cell. Physiol. 157:110-118 (1993).
Doyle et al., “A multidrug resistance transporter from human MCF-7 breast cancer cells,”Proc. Natl. Acad. Sci. USA26:15665-15670 (1998).
Lavie et al., “Agents that Reverse Multidrug Resistance, Tamoxifen, Verapamil, and Cyclosporin A, Block Glycosphingolipid Metabolism by Inhibiting Ceramide Glycosylation in Human Cancer Cells,”J. Biol. Chem. 272:1682-1687 (1997).
McAlroy et al., “Drug Extrusion,125I−Efflux and the Control of Intracellular [Ca2+] in Drug-Resistant Ovarian Epithelial Cells,”Exp. Physiol. 84:285-897 (1999).
Mestdagh et al., “Comparative Study of Intracellular Calcium and Adenosine 3',5'-Cyclic Monophosphate Levels in Human Breast Carcinoma Cells Sensitive or Resistant to Adriamycin®: Contribution to Reversion of Chemoresistance,”Biochem. Pharmacol. 48:709-716 (1994).
Morgan et al., “Multidrug resistance in MCF-7 human breast cancer cells is associated with increased expression of nucleoside transporters and altered uptake of adenosine,”Canc. Chemother. Pharmacol. 29:127-132 (1991).
Ogretmen et al., “Down-Regulation of Apoptosis-Related bcl-2 but not bcl-xLor bax Proteins in Multidrug-Resistant MCF-7/Adr Human Breast Cancer Cells,”Int. J. Cancer67:608-614 (1996).
Rubin, “The significance of biological heterogeneity,”Cancer and Metastasis Reviews9:1-20 (1990).
Schneider et al., “Multidrug Resistance-associated Protein Gene Overexpression and Reduced Drug Sensitivity of Topoisomerase II in a Human Breast Carcinoma MCF7 Cell Line Selected for Etoposide Resistance,”Cancer Res. 54:152-158 (1994).
Sinha et al., “Differential Formation of Hydroxyl Radicals by Adriamycin in Sensitive and Resistant MCF-7 Human Breast Tumor Cells: Implications for the Mechanism of Action,”Biochemistry26:3776-3781 (1987).
Wolffe et al., “Primary culture, cellular stress and differentiated function,”FEBS Letters176:8-15 (1984).
Wosikowski et al., “Altered Gene Expression in Drug-resistant Human Breast Cancer Cells,”Clin. Cancer Res. 3:2405-14 (1997).
Brooker Gary
DeBernardi Maria A.
Atto Bioscience
Canella Karen A.
Cooley Godward Kronish LLP
LandOfFree
Methods for diagnosing drug-resistant cancer cells or for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for diagnosing drug-resistant cancer cells or for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for diagnosing drug-resistant cancer cells or for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3995376